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TO THE EDITOR
Cathelicidins comprise an important
family of antimicrobial peptides that
are essential for protection of skin
against bacterial infection in mice
(Nizet et al., 2001), and are relevant
to infection in human skin diseases
such as atopic dermatitis (Ong et al.,
2002). The human cathelicidin gene
(Camp) is expressed as an inactive
precursor protein (hCAP18) and is
present in neutrophils, mast cells,
keratinocytes, and eccrine glands
(Braff et al., 2005). hCAP18 consists of
an N-terminal signal peptide, a cathelin
domain, and a C-terminal region en-
coding the antimicrobial domain
(Sorensen et al., 2001). After proteolytic
processing of hCAP18 to peptides such
as LL-37, the peptide exerts antimicro-
bial activity that protects the host from
infection. In this study we determined if
cathelicidin is produced by sebocytes,
thereby establishing its potential to add
to defense of the skin by this cell.
The sebaceous gland has been
suspected to provide protection to the
external skin surface, but its func-
tions were only recently understood
(Zouboulis, 2003). Lipids produced by
the sebocyte exhibit antibacterial acti-
vity (Georgel et al., 2005) and peptides
of the b-defensin family have been
found in human pilosebaceous units
(Chronnell et al., 2001). Since cathe-
licidin has synergistic activity with
b-defensins, it was of interest to deter-
mine the expression of cathelicidin in
the sebaceous gland.
hCAP18 mRNA was detected by
reverse transcriptase-PCR (RT-PCR)
in isolated human sebaceous glands
microdissected from normal scalp skin
(Figure 1a). Cathelicidin protein was
detected in sebaceous glands in normal
human scalp tissue examined with
anti-LL37 antibody (Murakami et al.,
2002; Figure 1b). Western blot analysis
of extracts from isolated human sebac-
eous glands demonstrated a single
band corresponding to LL-37 (Figure
1c). This finding is in contrast to
cathelicidin isolated from neutrophils,
where the predominant form seen was
the hCAP18 precursor (Sorensen et al.,
2001).
hCAP18 mRNA was also detectable
in SZ95 sebocytes (Zouboulis et al.,
1999) by quantitative real-time RT-PCR,
and was induced by 1,25(OH)2 vitamin
D3 (Figure 1d). The expression of
hCAP18 mRNA was also induced by
Propionibacterium acnes (P. acnes)
culture supernatant (Figure 1e). Cathe-
licidin protein was also detected by
immunofluorescence and this was
enhanced with 1,25(OH)2 vitamin D3
(100 nM) (Figure 1f). The concentrations
of cathelicidin detected by ELISA
were 0.17mg per 106 SZ95 sebocytes
(vehicle control) and 0.39 mg per 106
SZ95 sebocytes (100 nM 1,25(OH)2
vitamin D3) (Figure 1g).
To further define the response of
SZ95 sebocytes to vitamin D, the
expression of the vitamin D-dependent
gene CYP24A1 (24-hydroxylase), and
vitamin D receptor, was examined.
CYP24A1 mRNA was induced 28-fold
by 100 nM of 1,25(OH)2 vitamin D3
(Figure 1h). The vitamin D receptor
was abundantly detected by immuno-
fluorescence (Figure 1i). These results
confirmed that SZ95 cells were vitamin
D responsive.
To more precisely determine the
mass and sequence of the cathelicidin
peptide, SZ95 sebocytes were evalu-
ated by surface-enhanced laser deso-
rption/ionization–time of flight–mass
spectrometry with anti-LL37 antibody
capture. Surface-enhanced laser deso-
rption/ionization–time of flight–mass
spectrometry detected a single peak
with a molecular mass of 4,496-Da
(Figure 1j), identical to the expected
Abbreviations: P. acnes, Propionibacterium acnes; RT-PCR, reverse transcriptase-PCR; S. aureus,
Staphylococcus aureus
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Figure 1. Cathelicidin is present in sebaceous glands isolated from normal scalp, in isolated sebaceous gland extracts, and in SZ95 sebocytes, where it
is inducible by 1,25(OH)2 vitamin D3. (a) PCR amplification of hCAP18 mRNA from three independent isolates of normal scalp human sebaceous glands.
(b) Histological sections of normal human scalp tissue examined for cathelicidin expression by immunohistochemistry with the anti-LL37 antibody. Human
cathelicidin peptide was detected in both vertical and transverse scalp sections, and in eccrine structures, including glands and ducts. No staining was
detected in the tissue sections stained with preimmune IgG. (c) Human sebaceous gland extracts evaluated by western blot with antibody to LL-37. Right
two lanes show a single band at a size consistent with the expected 5-kDa mature form of LL-37 and similar to the LL-37 synthetic peptide in the left two
lanes. (d) Real-time RT-PCR for hCAP18 SZ95 sebocytes treated with 1,25(OH)2 vitamin D3 or the vehicle for 24 hours. (e) Real-time RT-PCR for hCAP18 in
SZ95 treated with P. acnes culture supernatant for 24 hours. (f) SZ95 sebocytes treated with the vehicle, or 100 nM 1,25(OH)2 vitamin D3 for 24 hours and
stained with anti-LL-37 antibody or preimmune IgG. (g) Analysis of cathelicidin in SZ95 sebocyte extracts evaluated by ELISA. (h) Real-time RT-PCR for
CYP24A1 in SZ95 treated with 1,25(OH)2 vitamin D3 (100 nM) or with the vehicle for 24 hours. (i) SZ95 sebocytes stained with anti-vitamin D receptor
antibody. (j) Surface-enhanced laser desorption/ionization–time of flight–mass spectrometry analyses of cathelicidin isolated from SZ95 sebocyte extracts.
A peak at 4,496-Da corresponding to the mature LL-37 peptide was detected in SZ95 sebocytes (**Po0.01; Student’s t-test, Bars¼ 20 mm). GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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mass of the LL-37 when processed in
neutrophils.
To investigate the relevance of this
finding to the antimicrobial function of
sebocytes, we next determined if LL-37
could kill bacteria such as Staphylo-
coccus aureus (S. aureus) and P. acnes,
both potential pathogens of the human
pilosebaceous unit. Under low-nutrient
conditions, synthetic LL-37 (8 mM) killed
100% of S. aureus wild-type strain
SA113 (ATCC 35556) (Figure 2a) and
synthetic LL-37 (4 mM) killed 100% of
P. acnes (Figure 2b). Acid-soluble
protein extracts of SZ95 sebocytes
also showed activity against S. aureus
(Figure 2c) and P. acnes (Figure 2d).
However, the amount of LL-37 in these
extracts was insufficient to explain the
antimicrobial activity: the concen-
tration of LL-37 in SZ95 acid-soluble
protein extracts as measured by ELISA
was 0.17mgml1 (0.038mM).
Since other antimicrobials such as
b-defensins (Chronnell et al., 2001)
and psoriasin (Glaser et al., 2005) are
expressed in sebocytes, and antimicro-
bial peptides have additive or syner-
gistic functions when combinded
(Nagaoka et al., 2000), we next exam-
ined the potency of LL-37 against
P. acnes when combinded with another
antimicrobial peptide found in the
sebocyte. Psoriasin alone (50 mgml1)
killed 80% of S. aureus (Figure 2e) and
95% of P. acnes (Figure 2f). When
combined with psoriasin (10 mgml1),
LL-37 was much more effective against
P. acnes (Figure 2g).
Taken together, these data show that
cathelicidin is expressed in sebocytes
and processed to the active peptide
LL-37, where it may potentially aid in
skin defense. Cathelicidin expression in
sebocytes was both constitutive and
inducible. This is reminiscent of the
expression of cathelicidin in keratino-
cytes, where it is induced in vivo by
infection, inflammation, or 1,25(OH)2
vitamin D3 (Frohm et al., 1997; Weber
et al., 2005). We show that SZ95 sebo-
cytes respond similarly to keratinocytes
and increased cathelicidin when
exposed to vitamin D3 or extracts of
P. acnes. This observation suggests a
potential novel role for vitamin D
in defense of the follicle. However, it
remains to be determined what is the
relative role of cathelicidin in sebo-
cyte antimicrobial action. The form of
cathelicidin produced by sebocytes
(LL-37) can kill skin microflora in vitro
such as S. aureus or P. acnes, but this is
only likely to be relevant when it
works together with other antimicrobial
agents. The total antimicrobial activity
in sebocytes is likely due to all anti-
microbial peptides acting together, and
in vivo is probably also aided by
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Figure 2. Synthetic LL-37 peptide, acid-soluble protein extracts of SZ95 sebocytes, and psoriasin kill S. aureus and P. acnes. LL-37 and psoriasin show
a synergistic effect against P. acnes. The antimicrobial activity of synthetic LL-37 (a, b), acid-soluble protein extracts of SZ95 sebocytes (c, d), and psoriasin
(e, f) was evaluated against S. aureus (a, c, e) and P. acnes (b, d, f, g) by solution killing assay. Bacteria were incubated for 3 hours at 37 1C in 10mM
sodium phosphate buffer (pH 6.5) supplemented with 100mM NaCl. Recombinant psoriasin was a gift from A. Bu¨chau and S. Kellermann, Dermatology,
Heinrich-Heine University, Du¨sseldorf, Germany. Values are percentage of living bacteria compared with the control. Data shown are representative of
triplicate determinations from three independent experiments.
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the antimicrobial action of fatty acids,
lipids, and the hostile pH of the skin
surface. Human b-defensin-2 mRNA
can also be induced in SZ95 sebocytes
by P. acnes (Nagy et al., 2006), and
psoriasin adds to the mixture. We show
here that combining only two antimi-
crobials (LL-37 and psoriasin) produced
a synergistic effect against P. acnes and
greatly increased the potency of cathe-
licidin. The actual concentration of
b-defensins, psoriasin, or other poten-
tial antimicrobial peptides in the sebac-
eous gland remains unknown, but the
current findings support the conclusion
that the sebaceous gland contributes
to epithelial defense by the release of
multiple antimicrobial molecules to
the skin surface. LL-37 may contribute
more to inflammation surrounding the
sebaceous gland than in antimicrobial
defense (Yamasaki et al., 2007).
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TO THE EDITOR
Acne remains both a distressing and
sometime serious skin condition with
both environmental and hereditary
factors playing an important role in this
disease. An example of the former is the
association of chloracne with dioxin
exposure, so much so that chloracne is
considered a clinical sign of dioxin
exposure (Pelclova et al., 2006); an
example of the latter is correlative
association between polymorphism in
the cytochrome P450 1A1 (CYP1A1)
gene and acne (Paraskevaidis et al.,
1998). CYP1A1 catabolises the meta-
bolism of xenobiotics, including the
oxygenation of polycyclic aromatic
hydrocarbons, with the most potent
known inducer of CYP1A1 being 2,3,
7,8-tetrachlorodibenzo-p-dioxin (Nohara
et al., 2006).
We have generated transgenic mice
that indicate basal CYP1A1 gene acti-
vity is restricted to the sebaceous gland
in mice. The transgene differs from that
described previously (Campbell et al.,
1996) in that the CYP1A1 gene promo-
ter drives the expression of enhanced
green fluorescent protein (EGFP), a red-
shift variant of wild-type green fluo-
rescent protein. EGFP is excitable using
blue light of wavelength 488 nm and is
detected by monitoring light of wave-
length 509 nm. The transgenic mice
were generated using standard pro-
nuclear microinjection on a mixed
C57/BL6CBA background. Activation
of EGFP can be studied in animals
without the use of sophisticated imageAbbreviations: CYP1A1, cytochrome P450 1A1; EGFP, enhanced green fluorescent protein
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